Xbrane Biopharma AB (XBRANE) — Cash Flow Reinvestment Rate

Latest as of December 2024: 0.37x

Xbrane Biopharma AB (XBRANE) has a Cash Flow Reinvestment Rate of 0.37x as of December 2024, reinvesting Skr34.60 Million (capex Skr17.30 Million plus investments Skr-17.30 Million) from operating cash flow of Skr93.91 Million. Check Xbrane Biopharma AB cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.37x
(Capex + Investments) / Operating CF

Total Reinvested

Skr34.60 Million
Capex + Investments

Operating Cash Flow

Skr93.91 Million
SEK

Capital Expenditures

Skr17.30 Million
SEK

Xbrane Biopharma AB Cash Flow Reinvestment Rate (2018–2018)

Historical reinvestment intensity for Xbrane Biopharma AB across 1 annual periods. Explore Xbrane Biopharma AB debt service capacity to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Xbrane Biopharma AB (2018–2018)

Year-by-year capital reinvestment analysis for Xbrane Biopharma AB. For live market cap and broader valuation context, see Xbrane Biopharma AB market cap and net worth.

Year Reinvestment Rate Total Reinvested (SEK) Operating CF Capex YoY Change
2018 0.07x Skr3.20 Million Skr46.71 Million Skr1.60 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow